PURPOSE: To examine the pharmacokinetics of amikacin and its pharmacokinetic pharmacodynamic (PKPD) relationship in neonates. To develop an alternative dosing strategy for amikacin in neonates. METHODS: A population PKPD analysis was performed using data collected from 80 neonates with gestational ages from 24 to 41 weeks. The final pharmacokinetic model analysed 358 amikacin concentrations. All neonates were > 72 hours postnatal age. Simulations were performed to develop a new dosing strategy. RESULTS: The final covariate model was clearance = 0.23 x (current weight/2)(0.691) x (postmenstrual age/40)(3.23) and volume of distribution = 0.957 x (current weight/2)(0.89). Following the logistic regression analysis of treatment failure, new amikacin target concentrations were estimated and used in development of an alternative dosing strategy. CONCLUSION: Simulation of a new dosing regimen yielded the following recommendations: 15 mg/kg at 36-h intervals, 14 mg/kg at 24-h intervals and 15 mg/kg at 24-h intervals for neonates < or = 28 weeks, 29-36 weeks and > or = 37 weeks postmenstrual age respectively.
PURPOSE: To examine the pharmacokinetics of amikacin and its pharmacokinetic pharmacodynamic (PKPD) relationship in neonates. To develop an alternative dosing strategy for amikacin in neonates. METHODS: A population PKPD analysis was performed using data collected from 80 neonates with gestational ages from 24 to 41 weeks. The final pharmacokinetic model analysed 358 amikacin concentrations. All neonates were > 72 hours postnatal age. Simulations were performed to develop a new dosing strategy. RESULTS: The final covariate model was clearance = 0.23 x (current weight/2)(0.691) x (postmenstrual age/40)(3.23) and volume of distribution = 0.957 x (current weight/2)(0.89). Following the logistic regression analysis of treatment failure, new amikacin target concentrations were estimated and used in development of an alternative dosing strategy. CONCLUSION: Simulation of a new dosing regimen yielded the following recommendations: 15 mg/kg at 36-h intervals, 14 mg/kg at 24-h intervals and 15 mg/kg at 24-h intervals for neonates < or = 28 weeks, 29-36 weeks and > or = 37 weeks postmenstrual age respectively.
Authors: N Bleyzac; V Varnier; J M Labaune; S Corvaisier; P Maire; R W Jelliffe; G Putet; G Aulagner Journal: Eur J Clin Pharmacol Date: 2001-09 Impact factor: 2.953
Authors: Catherine M T Sherwin; Roland S Broadbent; Natalie J Medlicott; David M Reith Journal: Eur J Clin Pharmacol Date: 2009-12 Impact factor: 2.953
Authors: Sílvia M Illamola; Hoa Q Huynh; Xiaoxi Liu; Zubin N Bhakta; Catherine M Sherwin; Theodore G Liou; Holly Carveth; David C Young Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: C Tayman; M N El-Attug; E Adams; A Van Schepdael; A Debeer; K Allegaert; A Smits Journal: Antimicrob Agents Chemother Date: 2011-06-27 Impact factor: 5.191
Authors: Michael Cohen-Wolkowiez; Mario Sampson; Barry T Bloom; Antonio Arrieta; James L Wynn; Karen Martz; Barrie Harper; Gregory L Kearns; Edmund V Capparelli; David Siegel; Daniel K Benjamin; P Brian Smith Journal: Pediatr Infect Dis J Date: 2013-09 Impact factor: 2.129
Authors: A Smits; R F W De Cock; K Allegaert; S Vanhaesebrouck; M Danhof; C A J Knibbe Journal: Antimicrob Agents Chemother Date: 2015-07-27 Impact factor: 5.191